Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service thrombectomy, IVC filters & venous stents cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (194 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 36 | 3,021 | 46% |
| 2020 | 27 | 2,882 | 48% |
| 2021 | 30 | 3,219 | 51% |
| 2022 | 25 | 3,014 | 53% |
| 2023 | 25 | 3,025 | 55% |
| 2024 | 24 | 2,696 | 57% |
| 2025 from claims | – | 3,381 3,103–3,577 | 58% |
| 2026 forecast | – | 3,459 3,044–3,992 | 58% |
| 2027 forecast | – | 3,524 3,013–4,200 | 59% |
| 2028 forecast | – | 3,590 2,995–4,396 | 59% |
| 2029 forecast | – | 3,656 2,986–4,585 | 60% |
| 2030 forecast | – | 3,723 2,982–4,770 | 60% |
Mechanical thrombectomy, IVC filter placement, and iliac venous stenting. Professional codes (what the surgeon bills): CPT 37187, 37184, 37191, 37238.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 58% of the cases CMS names in New York; 17 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 75% inpatient hospital, 8% hospital outpatient, 17% office. The share outside the hospital has moved −5 pts since 2019.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 14 | 1,998+1.6%/yr | +1.6%/yr | 1.5 | 9% | 2,310 in 2030+2.4%/yr |
| New Jersey | 25 | 1,782+1%/yr | +1%/yr | 1.7 | 28% | 1,690 in 2030−0.8%/yr |
| Massachusetts | 2 | 738−0.4%/yr | −0.4%/yr | 0.8 | 9% | 740 in 2030+0.1%/yr |
| Connecticut | 1 | 474−5.9%/yr | −5.9%/yr | 1.4 | 23% | 420 in 2030−1.9%/yr |
| New Hampshire | 0 | 145−3.6%/yr | −3.6%/yr | 0.6 | 0% | 220 in 2030+7.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 109 | 13,452−13%/yr | −13%/yr | 7.71.7× | 80% | 12,500 in 2030−1.2%/yr |
| Peripheral arterial intervention | 97 | 12,468−0.1%/yr | −0.1%/yr | 6.51.5× | 60% | 16,300 in 2030+4.6%/yr |
| Superficial venous ablation | 132 | 8,630−5.2%/yr | −5.2%/yr | 4.51.6× | 97% | 9,880 in 2030+2.3%/yr |
| Carotid revascularization | 32 | 1,508−6.4%/yr | −6.4%/yr | 0.80.7× | 0% | 1,510 in 20300%/yr |
| Aortic endografts (EVAR/TEVAR) | 7 | 818−5.7%/yr | −5.7%/yr | 0.51.1× | 0% | 860 in 2030+0.8%/yr |
Thrombectomy, IVC filters & venous stents in every state, and its device makers · Every procedure market in New York · Every state · Compare with Pennsylvania
Penumbra leads with 35% of company spending on these surgeons in 2025, +5 pts on 2024.
In 2025, 14 companies reported engagement with New York’s surgeons worth $1.1M in consulting, speaking, meals and travel tied to these products, about $45K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 22 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
New York’s own discharge file counts every inpatient stay, whatever the payer: 1,067 ivc filters stays at 40 hospitals in 2024, against the Medicare-only figures above. The most commercial of the busy ones is MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (40% commercial): where commercial rates leave the most room for a premium product.
| Hospital | Cases | Medicare | Commercial |
|---|---|---|---|
| NYU LANGONE HOSPITALS NEW YORK | 107 | 76% | — |
| NEW YORK-PRESBYTERIAN HOSPITAL NEW YORK | 72 | 58% | 26% |
| MONTEFIORE MEDICAL CENTER BRONX | 64 | 63% | 17% |
| MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES NEW YORK | 52 | 46% | 40% |
| ALBANY MEDICAL CENTER HOSPITAL ALBANY | 50 | 66% | — |
| VASSAR BROTHERS MEDICAL CENTER POUGHKEEPSIE | 48 | 69% | — |
| NEW YORK-PRESBYTERIAN/QUEENS FLUSHING | 44 | 82% | — |
| NEW YORK-PRESBYTERIAN/BROOKLYN METHO BROOKLYN | 44 | 59% | — |
New York only: MedaRep has no other state’s all-payer file yet. Counted by principal procedure (IVC filters: filters only: thrombectomy is not a category of its own.). Medicare here includes Medicare Advantage. A hospital with 10 or fewer such stays, or a payer share of 10 or fewer, is not shown. Source: New York State Department of Health, SPARCS de-identified inpatient discharges (health.data.ny.gov). The New York State Department of Health makes no representation, warranty or guarantee relating to the data or analyses derived from these data. Accessed 2026-11-11.